Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2022 ∙ Meggiolaro, A. Sane Schepisi, M. Nikolaidis, G. F. Mipatrini, D. Siddu, A. Rezza, G.

Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Meggiolaro, A. Sane Schepisi, M. Farina, S. Castagna, C. Mammone, A. Siddu, A. Stefanelli, P. Boccia, S. Rezza, G.

Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Piechotta, V. Mellinghoff, S. C. Hirsch, C. Brinkmann, A. Iannizzi, C. Kreuzberger, N. Adams, A. Monsef, I. Stemler, J. Cornely, O. A. Bröckelmann, P. J. Skoetz, N.

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Notarte, K. I. Ver, A. T. Velasco, J. V. Pastrana, A. Catahay, J. A. Salvagno, G. L. Yap, E. P. H. Martinez-Sobrido, L. B. Torrelles J Lippi, G. Henry, B. M.

Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Ghazy, R. M. Ashmawy, R. Hamdy, N. A. Elhadi, Y. A. M. Reyad, O. A. Elmalawany, D. Almaghraby, A. Shaaban, R. Taha, S. H. N.

Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Administration
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2022 ∙ Li, X. Yang, X. Ning, Z.

Efficacy and safety of COVID-19 inactivated vaccine: A meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Zhang, L. Jiang, L. Tian, T. Li, W. Pan, Y. Wang, Y.

Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Graña, C. Ghosn, L. Evrenoglou, T. Jarde, A. Minozzi, S. Bergman, H. Buckley, B. S. Probyn, K. Villanueva, G. Henschke, N. Bonnet, H. Assi, R. Menon, S. Marti, M. Devane, D. Mallon, P. Lelievre, J. D. Askie, L. M. Kredo, T. Ferrand, G. Davidson, M. Riveros, C. Tovey, D. Meerpohl, J. J. Grasselli, G. Rada, G. Hróbjartsson, A. Ravaud, P. Chaimani, A. Boutron, I.

Efficacy and safety of COVID-19 vaccines

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
High
2022 ∙ Toubasi, A. A. Al-Sayegh, T. N. Obaid, Y. Y. Al-Harasis, S. M. AlRyalat, S. A. S.

Efficacy and safety of COVID-19 vaccines: A network meta-analysis

  • Adolescents
  • Adults
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2022 ∙ Graña, C. Ghosn, L. Evrenoglou, T. Jarde, A. Minozzi, S. Bergman, H. Buckley, B. S. Probyn, K. Villanueva, G. Henschke, N. et al.,

Efficacy and safety of COVID‐19 vaccines

  • Children
  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Moderate
Loading...